Regeneron Concession Narrows Covid Antibody-Cocktail Patent Suit

Regeneron Pharmaceuticals Inc. agreed that its Covid-19 “antibody cocktail” was developed using technology that, unless it’s found to be shielded from liability under a legal “safe harbor,” would infringe a California biotechnology company’s valid patent, in a deal narrowing the case.

Regeneron and Allele Biotechnology and Pharmaceuticals Inc. reached their agreement based on Judge Philip M. Halpern’s Dec. 5 claim-construction order, according to a stipulation and order issued Monday in the US District Court for the Southern District of New York.

The companies’ deal leaves damages, willfulness, and the safe-harbor defense the only remaining issues in the litigation over ...